4.2.1. Nutritional Requirements

Nutritional deficiencies, usually because of owner ignorance, are common problems in pet monkeys. The nutritional requirements of non-human primates are quite complex and vary greatly between the different species. Diets are complex and consist of fruits, vegetables, commercially available monkey chow, and food enrichment items. Primates may be primarily omnivorous, frugivorous, vegetarian, and foragers and their social standing may affect how much and what they eat.

Commercially available dietary products for both New World and Old World primates offer the most balanced nutrition. Vitamin supplementation is required if not using a commercially prepared food. This is critical for New World Primates who rely heavily on exogenous sources of vitamins C and D3. Foraging needs should be met in order to maintain mental enrichment standards.

Vitamin C deficiency is a common problem in NHP that are not properly supplemented. Although most commercial feeds have adequate levels of vitamin C at the time of packaging, after 90 days of storage, these levels decrease dramatically. Vitamin C deficiency typically presents as scurvy, with clinical signs including swelling of the epiphyses of long bones, hemorrhaging of the gums and periosteum and hydrocephalus. Maintenance levels of vitamin C are 1-4 mg/kg BW daily and treatment doses are up to 25 mg/kg twice daily for 5 days in severe cases.

Vitamin D3 deficiency: Both New World (esp. marmosets and tamarins) and Old World primates living in environments without sufficient sunlight require vitamin D3 supplementation. This should be present in commercial monkey diets. Avoid D2 or ergocalciferol since these cannot be utilized. Monkeys deficient in vitamin D3 develop soft bones (metabolic bone disease), long bone deformities, multiple fractures, and increased levels of serum alkaline phosphatase. Treatment consists of 2000 IU/kg vitamin D3 added to the diet. This treatment halts the progression of the process but the major bone deformities are irreversible. UVB or natural sunlight may be helpful in treatment and should be considered for prevention of the problem.

4.2.2. Hemochromatosis

Hepatic iron storage disease has been reported in lemurs. This is likely due to excessive dietary iron and the lack of tannins in the diet which are found in their natural environment (similar to the etiology suspected for toucans). Lemurs should be fed a special lemur commercial diet. Citrus fruits and/or added ascorbic acid should be avoided since this will increase the availability of iron. Hepatic neoplasia may be a consequence of hemochromoatosis.

5.1.1. Herpes Viruses

This viral family is one of the more common groups of viruses found in NHPs, as well as one of the best publicized. Herpes infections are responsible for a wide range of symptoms ranging from inapparent infections to fatal disease.

5.1.1.2. Other Pathogenic Herpes Viruses

Other herpes viruses that can be of concern, either because of zoonotic risks or transmission between susceptible species of monkeys are:

• Herpesvirus Hominis (Herpesvirus simplex): one of the oldest viral infections of man, two variants have been known to be transmissible from man to monkeys: HSV-1 and HSV-2 (experimentally). In owl monkeys, tree shrews, gibbons, marmosets and cebus monkeys, human herpesvirus causes high morbidity and mortality.
• Herpesvirus tamerinus : viral herpes in tamarins and marmosets that may cause severe clinical disease, including hepatitis, in those species. Can be devastating in owl monkeys. Appears to also be found in squirrel monkeys, cinnamon ringtails and spider monkeys often causing slight to no clinical disease.
• Epstein-Barr virus
• Spider Monkey herpesvirus : a herpes virus found in spider monkeys, and occasionally in capuchins, marmosets and wooly monkeys. Can be fatal in marmosets.
• Simian Varicellalike herpesviruses : This is a group of seven simian herpesviruses that closely resemble varicella-zoster in man. They include Liverpool vervet monkey virus, Patas monkey herpesvirus, Delta herpesvirus, Medical Lake macaque virus, Herpesvirus cyclopis, Chimpanzee herpesvirus, and Gorilla herpesvirus. Infection with any of the seven viruses, in general, causes high morbidity and mortality and varies greatly depending on the virus and species involved. Clinical signs can range from severe dermatitis to a severe, life threatening and often-fatal exanthematous disease.
• Simian Cytomegalovirus (CMV) : Cytomegalovirus is relatively host specific and in its natural hosts tends to cause latent infections with relatively no clinical signs.

5.1.2. Measles

Measles is an RNA paramyxovirus related to canine distemper and rinderpest. Although measles is not considered a naturally occurring disease in NHPs, it is one of the most frequently reported viral diseases. Infection in NHPs occurs as a result of human contact, and then the infected primate can shed the virus, and re-infect man. Clinical signs in NHP can range from fever, conjunctivitis, coryza, bronchitis and Koplik spots on oral mucosa. A skin rash may appear on the third to seventh day and leukopenia is common. Complications that may occur include otitis media, pneumonia, encephalitis, and enteritis. Measles infection in New World primates (marmosets, tamarins, and owl monkeys) is usually fatal and can be easily avoided by good husbandry practices and a vaccination program using an attenuated vaccine for both animals and staff.

5.1.3. Poxviruses

There are four types of poxviruses that infect NHP and three of these are zoonotic to humans. They can infect numerous species of NHP, usually presenting as typical cutaneous lesions, which can be severe enough to cause death. Monkeypox, caused by Monkeypox virus, is serologically related to smallpox virus in humans. The disease is characterized by proliferate dermal ulcerations and vesicles. Adult monkeys may get fevers but death is rare except in infants. Because Monkeypox is serologically related to smallpox, it has the potential to be devastating in unvaccinated human populations. Benign epidermal Monkeypox is a nonfebrile disease seen in macaques and is serologically related to Yaba tumor virus and is known as Yaba pox or Yaba like pox. The virus is identical to the agent that produces Tanapox in children in Africa. Yaba virus disease is seen in rhesus monkeys, baboons and rarely man. It appears as large subcutaneous, tumor like lesions.

5.1.4. Rabies

Nonhuman primates housed in rabies endemic areas are as susceptible to rabies as man. Only killed vaccines or vaccines suitable for use in humans should be used to vaccinate NHPs.

5.1.5. Polio

All NHP are extremely susceptible to polio, especially the great apes. In areas where polio vaccination of humans is routine, this usually does not present a problem to these animals due to the lack of disease in the human population. Because of their heightened sensitivity to polio, all monkeys, especially the great apes, should be vaccinated for the disease as juveniles.

5.1.6. Hepatitis

The viral infectious hepatitis virus (Hepatitis A) has been identified in chimpanzees, patas, wooley monkey, gorilla, cebus, aotus, and some tamarins. Antibodies to Hepatitis B (a lipid-enveloped DNA virus) have been reported in chimps and baboons, but the status of natural infection is not known. All great apes should be considered to be at risk for this infection (vaccination with the human product is available). Hepatitis B is one of the more commonly reported blood-borne pathogens isolated in the human health care setting. Most human cases that have been contracted from NHPs have resulted from contact with young or recently imported chimps. No fatalities have been reported as a result of a zoonotic transmission of hepatitis.

Hepataits C has been reported in chimpanzees and produces a chronic active hepatitis, cirrhosis and hepatocellular carcinoma.

5.1.7. Lymphocytic Choriomeningitis Virus (LCMV)

This rodent virus has been determined to be the cause of Callitrichid hepatitis. It presents as acute onset of lethargey anorexia and elevated liver enzymes. There is high mortality associated with this infection in captive collections. Monkeys are thought to get this infection from mice in the exhibit, or from being fed pinkie mice as treats in their diet. This practice should be avoided. This is a potential zoonotic concern.

5.1.8. Wasting Disease in Marmosets

The etiology of this syndrome has not yet been determined and may be the end result of several different diseases. Clinical signs usually involve weight loss and diarrhea. A lymphocryptovirus is one of the suspected etiologies, as well as gluten intolerance, vitamin E/selenium deficiency or stress induced. The pathologic lesion consists of enteric lymphoproliferation. Differential diagnosis should include bacterial enteritis (Salmonella, Campylobacter, E. Coli)

5.1.9. Other Zoonotic viruses

• Parainfluenza viruses
• Mumps
• Respiratory Syncytial Virus
• Rotavirus
• Poliovirus
• Coxsackievirus
• Rhinovirus

5.1.10. Filoviruses

Filoviruses belong to the family Filoviridae, one of several groups of viruses that can cause hemorrhagic fever in animals and humans. Marburg virus was the first filovirus to be discovered in 1967 in a shipment of African green monkeys imported into Marburg, Germany. There were 31 human cases associated with this outbreak and 7 of those were fatal. Then in 1976, Ebola virus was recognized in Zaire. Ebola virus has now been subtyped into these four distinct viral groups: Zaire, Sudan, Ivory Coast, and Ebola-Ralston. These relatively newly recognized strains of filoviruses have been given special attention due to the viral outbreak in a Virginia quarantine facility in recently imported cynomolgus monkeys (Ebola-Reston). No filovirus-related illness has been observed in any humans who have been in contact with these infected monkeys, but antibody titers have been detected, indicating transmission did occur. The three subtypes that are known to cause disease in humans are Ebola-Zaire, Ebola-Sudan and Ebola-Ivory Coast. The disease is called Ebola Virus Hemorrhagic Fever and clinical signs in both humans and NHP are: fever, chills, headaches, muscle aches, and anorexia. As the disease progresses, vomiting, diarrhea, abdominal pain, sore throat, and chest pain may develop. A coagulopathy then develops and bleeding may occur from injection sites as well as into the gastrointestinal tract, skin, and internal organs. Because of the high mortality rate from human filovirus infections (Ebola, Marburg-Europoe, Sudan and Zaire strains), the CDC has updated regulations and inspections of imported primates. Recent evidence has shown that wild primates, especially the great apes, may be susceptible to naturally occuring Ebola outbreaks in Africa. Current outbreaks are severely threatening key populations of lowland gorillas in central Africa (see CM Challenge).

5.1.11. Retroviruses

There are two groups of retroviruses that are endemic in human populations, the human T cell leukemia / lymphotropic viruses (HTLV) types I and II and the human immunodeficiency viruses (HIV) types 1 and 2. Non-human primates are the natural hosts for a variety of retroviruses including simian immunodeficiency virus (SIV), simian spumaviruses (simian foamy viruses (SFV), simian T-lymphotropic viruses (STLV), and/or simian type D retroviruses. All of these viruses cause life long infections in non-human primates and may be transmissible through sexual contact, blood, bodily fluids or breast milk. The risk of transmission of simian retroviruses to humans following occupational exposure to NHP is not totally understood, but is being studies. In 1993, the CDC and the National Institutes of Health implemented a voluntary testing and counseling surveillance program for SIV following detection of SIV in a worker at a primate facility. This study was later expanded to include voluntary testing and counseling for exposures to SFV, STLV, and simian type D retroviruses. There are significant implications for laboratory workers and zoo personnel that work with NHPs.

Simian Immunodeficiency Virus

• SIVs are lentiviruses, morphologically similar and biologically related to HIV-1 and HIV-2. SIV can cause acquired immunodeficiency syndrome (AIDS) - like illnesses in susceptible macaque monkeys and when it crosses from host-specific species to non-host specific species.
• SIV strains are not usually pathogenic in their natural host species.
• Presently monkeys with SIV are used extensively in the study of AIDS. SIV is genetically and antigenically related to HIV-2, resulting in substantial serological cross-reactivity. All of the simian viral isolates have characteristics in common with HIV, including some serological cross reactivity and suspected immune suppression resulting in clinical disease.
• Evidence of SIV infection has been reported for 30 different species of African nonhuman primates (see table 3). Two of these viruses, SIV_cpz from chimpanzees and SIV_sm from sooty mangabeys, have been shown to be the source of HIV1 and HIV2 and acquired immunodeficiency syndrome (AIDS) in humans. The relationship between simian retroviruses and the disease in humans is a great concern, especially with the recent increase in the Bushmeat Trade. Blood donation and organ donation research is also concerned with possible transmission of these viruses. There have been at least nine documented cases of humans infected with SIV (Hahn, et. al).

Table 3: African non-human primates infected with SIV

from Hahn, et al..

Foamy Viruses (Spumavirus genus of Retroviridae : SFV or Simian Spumaviruses)

• are more than 50% prevalent in captive NHP colonies of New and Old world origin.
• Spumaviruses differ from other retroviruses in several respects including the viral polymerase gene is expressed from a spliced sub-genomic RNA and the extracellular particle contains large amounts of reverse-transcribed DNA. Presently there are five antigenically distinct SFVs, three of which are: SFV-6 (chimpanzee), SFV-3 (African Green monkey), and SFV-2 (macaque).
• SFV can be readily isolated from infected animals saliva or from peripheral blood lymphocytes and it has been isolated in approximately 3% of tested laboratory and zoo workers with NHP exposure.
• To date, there have been no ill effects to health in either the humans that are positive for SFV or the positive NHP. This virus has been referred to as the virus in search of a disease, because it does have the capacity to incorporate itself into DNA and is routinely transmitted between NHP without signs of disease.

Simian Retrovirus 1

• (Type D retrovirus) has been documented to cause a form of chronic wasting immunodeficiency disease in several primate species, including the natural hosts.
• 0 - 90% of Asian macaques can be infected in a collection
• This disease has also been seen in Talapoins and Gelada baboons

Talapoin monkeys Miopithecus talapoin

Simian T-cell Lymphotropic Virus type 1

• STLV1 shares an extensive genomic sequence with human T-lymphotropic virus type 1 (HTLV1)and is associated with T-cell lymphomas in non-human primates.
• It is also pathogenic in natural hosts
• There is a 6.8% seroprevalence in susceptible captive populations

5.2.1. Mycobacterial Spp.

Mycobacteria are responsible for tuberculosis, an increasingly rare disease in captive primates. Old world species of primates appear to be more susceptible than New World species. Historically, the three major species of Mycobacteria - avium, bovis, and tuberculosis, have been incriminated as causing disease in NHPs. Recently, there have also been reports of atypical mycobacteria in NHPs. The primary route of transmission is through inhalation or ingestion.

Clinical disease can be hard to detect until the disease is in advanced stages. Clinical tuberculosis causes severe weight loss, lethargy, and coughing and is almost always fatal in NHP. In both humans and NHPs the skin test detects only TB exposure, not active disease. Active disease is diagnosed either by recovery of the organisms in culture or by thoracic radiographic lesions consistent with active TB. PCR and other amplification tests can also detect organisms. Treatment of positive, clinical NHP is not advised at this time due to both the fear of developing resistant strains of Mycobacteria as well as the risk to human handlers. All owners of NHP and others having contact with them, including veterinary staff, should be TB tested annually and if positive, also have thoracic radiographs annually under the guidance of a TB specialist.

5.2.2. Pseudotuberculosis

Yersinia pseudotuberculosis is a zoonotic, infectious bacterial agent that has a worldwide distribution and is endemic in European countries. The infection can affect a wide range of host species but in particular has caused numerous deaths in tamarins, marmosets and Goeldi's monkeys in captivity. Clinical signs of infection can range from asymptomatic animals that shed the bacteria, to nonspecific signs of systemic or enteric diseases or sudden death that may be difficult to diagnose. This disease can also produce a wasting syndrome. The organism can live in the soil for long periods of time and asymptomatic animals, combined with the difficulties in culturing the organism from rectal or fecal swabs, can all lead to difficulties in controlling the organism. Preventative measures such as quarantine, good sanitation, good hygiene, especially in food preparation, and pest control, together with a vaccination program in endemic areas, are all recommended in preventing infection, although vaccination is not 100% effective.

5.2.3. Bacterial Meningitis Syndrome

This syndrome seen in great apes has many etiologic agents and may be zoonotic depending on the agent involved. The syndrome can present as either acute or chronic meningitis and prompt, effective diagnosis and treatment is required to avoid fatalities or chronic, persistent clinical impairments. The most prevalent pathogens implicated are Streptococcus pneumoniae, Neisseria meningitides, and Hemophilus influenza type B.The N. meningitides and H. influenza type B are threats to exposed humans.

5.2.4. Campylobacter jejuni

Campylobacter jejuni is a common fecal bacterium found in old and new world monkeys. Asymptomatic shedding of large numbers of bacteria in feces is common. Some monkeys may exhibit mild to severe diarrhea accompanied by weight loss, dehydration and bloody feces. The disease in humans may cause debilitating diarrhea and people may also shed the bacteria asymptomatically.

5.2.5. Shigellosis

Shigellosis is common among old world monkeys. The most common species cultured in old world monkeys is Shigella flexneri, while the most common isolate from humans is S. sonnei. In most cases of zoonotic transmission humans are the reservoir for NHP infections. Shigella is very contagious to humans and children are very susceptible. Diarrhea with blood and mucus is the most common clinical sign in both humans and NHP. Shigella, if left untreated, may be rapidly fatal to NHP and human children.

5.2.6. Other Bacteria

Yersinia enterocolitica, Salmonella, and E. coli all can also be cultured from the GI tract of NHPs and are capable of causing zoonotic disease in humans. These organisms may or may not be associated with clinical disease in NHPs and one negative culture does not indicate a disease free animal.

5.3.1. GI parasites

Giardia lamblia, Cryptosporidium, Enterocytozoan bieneusi, Balantidium coli, and Entamoeba histolytica are all intestinal protozoa that can infect monkeys and humans. Diarrhea in both monkeys and humans can range from mild to severe. There have been a few documented cases of fatalities in neonatal and juvenile monkeys due to these protozoa.

There are also many nematode parasites seen in NHP. Some of the most frequently seen are Oesophagostomum, Strongyloides, and Dipetalonema species. Other GI parasites sometimes seen are Hymenolepis nana, Echinococcus granulosus and Prosthenorchus elegans. P. elegans is of particular importance in New World primates, especially tamarins and marmosets, and has been associated with high mortality in those species of monkeys. Preventative anthelmintics as well as diligent fecal screens and cockroach control are critical in maintaining these animals.

5.3.2. Blood borne parasites

Blood borne parasites are rare in captively bred monkeys but may be seen in wild caught monkeys. Trypanosoma cruzi has been isolated from recently imported squirrel monkeys, tamarins and marmosets and causes Chagas' disease. This is a disease that causes debilitation and cardiomyopathy in man.

6.2.1. Vaccination recommendations for NHP

6.2.2. TB testing

TB testing in a ring-tailed lemur

The recommended method of tuberculin testing is to use 0.1 ml of a 1:10 dilution of mammalian tuberculin approved by the USDA (equivalent to 1500 or more units of old tuberculin). A 25 to 27 gauge, 1/2 needle is used to inject the tuberculin intradermally, usually in the upper eyelid. The nipple can be used as a secondary confirmatory site. The test should then be read at 24, 48, and 72 hours. Any reaction should be considered positive and the animal should be immediately quarantined until further diagnostics can be done. These diagnostics may include radiographs, sputum, fecal and blood cultures, gastric lavage for cytology and culture, and comparative TB tests and PCR.

6.2.3. Other common problems

• Dental problems

  Periodontal disease in a monkey.

• Cardiac disease
  • Longlived
  • Chronic stress
  • Malnutrition
  • Primary cause of 42% of deaths in gorillas

6.3.1. For non-human primates weighing <12 kg

A squeeze cage, where either the back or front is moveable and able to squeeze the primate against the bars for easy injection, is preferable. Not many veterinary clinics have these cages available, although if a large percentage of clients own NHP as pets, they are well worth the investment. At least one handler, plus the veterinarian, is needed for adequate restraint. The owner of the primate should not be one of the handlers. For a physical examination, the primate should be firmly grasped from behind, just proximal to the elbows. The arms should be gently rotated so that the elbows are almost touching behind the animals back. Excessive force may result in fractures, especially in severely debilitated and undernourished animals. Once the arms have been properly restrained, the ankles should be grasped and the legs extended until the NHP is in a stretched position.

6.3.2. For non-human primates weighing 12 - 15 kg

At least two handlers are needed. It is very important to never underestimate the strength of these animals. Heavy leather gloves may be worn, although restraint may be difficult with these on and they may provide a false sense of security. Many NHP have penetrated such gloves with their teeth. The use of nets, grab poles and rabies poles may be sufficient to give the veterinarian time to quickly inject the NHP with a tranquilizer. Non-human primates are very intelligent and have been known to grab syringes and redirect them towards the handler or veterinarian! They also have a tremendous memory and what works once, may not work again.

6.3.3. Animals over 15 kg

Unless severely debilitated, should be chemically restrained in order to prevent human injury.

Recovering from anesthsia

6.4.1. Premedications

The use of premedications may make anesthetic induction smoother, both from a handling point of view as well as decreasing the amount of drug needed to induce anesthesia. The two most commonly used premedications for NHP are diazepam (Valium) and midazolam (Versed). In a healthy animal, the owner may give these premedications at home approximately 30 minutes before presentation at the veterinary clinic. It must be stressed to the owner that they cannot be given in a large volume of food or liquid because of increasing the chances of regurgitation and vomiting during anesthetic induction.

6.4.2. Tranquilizers and anesthetics

Intramuscular dosing is the only practical route to use on most non-human primates. This limits the choices of drugs to those that can be given in small volumes and that are not muscle toxic. Hand injections require either some type of mechanical restraint first (trained handlers, nets, squeeze cages, rabies poles etc.) or a pole syringe. Pole syringes can prove very dangerous due the non-human primates ability to grasp objects quickly and redirect them to the injector! Remote drug delivery systems can also be used effectively. These include the use of blow darts and tranquilizer guns. Once again, NHP have been known to throw the tranquilizing darts back at the veterinarian, sometimes with very accurate aim!

Premedications may help in the ease of drug administration with all of the delivery systems. Atropine sulfate (0.02 - 0.04 mg/kg IM) can be given for prevention of bradycardia and hypersalivation.

• Ketamine hydrochloride has traditionally been the drug of choice. It is generally safe, inexpensive, and allows for adequate restraint for minor procedures at lower doses (8-10 mg/kg IM) and surgical anesthesia at higher doses (15-20 mg/kg IM). It can be used alone or in combination. If the volume to be administered is large, the dose can be split up into multiple sites or a fraction of the initial dose may be enough to facilitate physical restraint and subsequent dosing. Ketamine is also available in more concentrated solutions, greater than the standard 100 mg/ml, from compounding pharmacies. A 200 mg/ml solution is available from Franck's Pharmacy, 202 SW 17^th St. Ocala, Fl 34474 (352) 622-4148. One disadvantage of Ketamine is the lack of a reversal agent. It also has been known to cause seizures in lemurs. Recovery from Ketamine does tend to be rough and a small dose of diazepam (0.1-0.25 mg/kg IM) given at the end of the procedure may help.
• Tiletamine and zolazepam (Telazol) is licensed for use in non-human primates. Standard dosing of Telazol is 2-6 mg/kg IM. Recovery time from Telazol tends to be somewhat prolonged when compared to Ketamine. There is no reversal agent for Tiletamine, but flumazenil (Romazicon, very expensive), a benzodiazepine receptor antagonist (0.2 mg IV every 30-60 sec until desired effect - max. dose 1 mg {human dose}) can be used to reverse the zolazepam. The short half-life of flumazenil (approx. 1 hr) makes repeated dosing sometimes necessary.
• Medetomidine combinations have recently gained popularity in the literature for anesthesia in NHPs. Medetomidine alone has been proven effective as a sedative-analgesic in a number of other species, but has not worked as a complete immobilizing agent. In addition to the profound sedation and analgesia seen with alpha2-agonists such as medetomidine, significant effects on the cardiovascular system are also seen and need to be considered before this drug is chosen. Intense vasoconstriction with compensatory bradycardia may be seen. Reversal of medetomidine with atipamezole at approximately five times the dose of medetomidine (200 ug/kg IM or a partial dose IV and the rest IM) is an advantage of these combinations.

  Medetomidine - Ketamine combination for induction followed by isoflurane anesthesia has been proven to be safe and effective in gorillas and chimpanzees. Drug volumes and inhalation gas concentrations needed are both decreased with minimal cardiovascular side effects seen. Reversal should be rapid, smooth and complete.

  Medetomidine - Zolazepam and Tiletamine combination has been evaluated as an immobilizing agent in Southeast Asian primates. This combination produced smooth inductions and complete immobilizations with minimal cardiovascular side effects.

6.4.3. Analgesics

Analgesics should be routinely used whenever post-operative pain is expected. Immediately post-operatively, injectable analgesics are preferred. Oral dosing once the animal goes home is ideal, however, it can sometimes be very difficult to medicate NHPs orally. The discriminating primate may detect even the most carefully disguised drug. There are compounding pharmacies now available that will make up medications in a variety of flavors and formulations. If a procedure is scheduled enough in advance, these compounded formulations are usually the easiest way to medicate the NHP. Cutaneous pain control methods such as Fentanyl patches are generally not successful because they need to be applied prior to the procedure and it is hard to adequately restrain the NHP from peeling them off.

7.1.1. Books

Bennett, B. Taylor, Christian R. Abee, and Roy Hendrickson, eds. Nonhuman primates in biomedical research, vol. 1: Biology and management, vol. 2: Diseases. San Diego: Academic Press, 1995-1998, 2 vols. ISBN 0120886618 (v.1) and 0120886650 (v.2).

Colley, Rob, ed. Marmosets and tamarins in captivity. Bristol: The British Association of Wild Animal Keepers, 1993.

Committee on Well-Being of Nonhuman Primates, Institute for Laboratory Animal Research, Commission on Life Sciences, National Research Council. The psychological well being of nonhuman primates. Washington, DC: National Academy Press, 1998. ISBN 0309052335.

Flecknell, P.A. Laboratory animal anaesthesia: a practical introduction for research workers and technicians, 2^nd ed. Academic Press, 1996. ISBN 0122603613.

Fowler, Murray E. and Miller, R. Eric. Zoo and Wild Animal Medicine, 5th ed. Saunders, 2003. Chapters: 37-39.

Fox, JG, Cohen, BJ, Loew, FM. Laboratory Animal Medicine. Orlando, Florida: Academic Press; 1984

Hawk, C. Terrance and Steven L. Leary, comp. Formulary for laboratory animals. Ames, Iowa: Iowa State University Press, 1995. ISBN 0813824222.

Hrapkiewicz, Karen, Laticia Medina and Donald D. Holmes. Clinical medicine of small mammals & primates: an introduction, 2^nd ed. London: Manson, 1998. ISBN 1874545952.

Johnson, David K., Robert J. Russell and Jim A. Stunkard. A guide to diagnosis, treatment and husbandry of nonhuman primates. Edwardsville, Kan.: Veterinary Medicine Pub. 1981.

Kirkwood, James K. and Katherine Stathatos. Biology, rearing, and care of young primates. Oxford University Press, 1992. ISBN 0198547331.

Physician's Desk Reference. Medical Economic Co. 1998; 2494

Scott, GBD. Comparative Primate Pathology, 1992. ISBN 0198576404.

7.1.2. Articles

Bielli M., Lauzi S., Pratelli A., Martini M., Dall'Ara P., Bonizzi L. Pseudotuberculosis in Marmosets, Tamarins, and Goeldi's Monkeys (Callithrichidae / Callimiconidae) Housed at a European Zoo. Journal of Zoo and Wildlife Medicine 30(4): 532-536, 1999.

Brooks, P. Are You Sure You Want A Monkey? Brochure- The Simian Society of America, Inc.

Carpenter JW. Mashima TY. Rupiper DJ. Exotic Animal Formulary. Greystone Publications. 1996; 272-274

Cogswell, F. B. Malaria and Piroplasms of Non-Human Primates, IN: Companion and Exotic Animal Parasitology, Bowman D.D. (Ed.) IVIS Website.

Ellenberger, U. Factors influcencing the parasite status of gorilla subspecies (Gorilla beringei graueri, Borilla beringei beringei, Gorilla gorilla gorilla): a plea for a multidisciplinary approach in conservation medicine. Proceedings of the AAZB and IAAAM Joint Conference, 2000: 160-165.

Fahlman A. Bosi EJ. Nyman GN. Immobilization of Southeast Asian Primates with Medetomidine, Zolazepam and Tiletamine, and Reversal with Atipamezole. Proc. American Assoc of Zoo Veterinarians 1999: 334.

Gao, Feng, et al. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes.Nature, 397, 1999: pp. 436-441.

Hahn BH. Shaw GM., De Cock KM., Sharp PM. AIDS as a Zoonosis: Scientific and Public Health Implications. Science Vol. 287, 28 January 2000 : 607-614.

Heneine W., Switzer WM., Sandstrom P., Brown J., Vedapuri S., Schable CA., Khan AS. Lerche NW., Schweizer M., Neumann-Haefelin D., Chapman LE., Folks TM. Identification of a Human Population Infected with Simian Foamy Viruses. Nature Medicine, Vol. 4., No. 4, April 1998.

Hoop RK. Public Health Implications of Exotic Pet Mycobacteriosis. Sem. in Avian and Exotic Pet Med. January 1997; Vol 6, No 1; 3-8.

Horne WA. Norton TM, Loomis MR. Cardiopulmonary Effects of Medetomidine-Ketamine-Isoflurane Anesthesia in the Gorilla (Gorilla gorilla) and Chimpanzee (Pan troglodytes). Proc. American Assoc of Zoo Veterinarians 1997: 140-142.

Horne WA. Wolfe BA. Norton TM. Loomis MR. Comparison of the Cardiopulmonary Effects of Medetomidine-Ketamine and Medetomidine-Telazol Induction on Maintenance Isoflurane Anesthesia in the Chimpanzee (Pan troglodytes). Proc. American Assoc. of Zoo Veterinarians and American Assoc. of Wildlife Veterinarians joint conf. 1998: 22-25.

Ialeggio DM. Mycobacterial Disease in the Nonhuman Primate. Sem. in Avian and Exotic Pet Med. January 1997; Vol 6, No 1; 34-39.

Ialeggio DM. Practical Medicine of Primate Pets. The Compendium, Small Animal October 1989; Vol. 11, No. 10; 1252-1258.

Johnson-Delaney CA. Nontraditional Animals for Contact with Immunosuppressed People: Precautions Against Zoonotic Disease Transmission. Proc. American Assoc of Zoo Veterinarians 1997:100-106.

Johnson-Delaney CA. Potential Zoonoses from Nontraditional Pets with Particular Attention to the Immunosuppressed Pet Owner. J Small Exotic Animal Med 1993; 2(3): 103-111.

Kalter SS. Infectious Diseases of Nonhuman Primates in a Zoo Setting. Zoo Biology Supp. 1989; 1:61-76.

Lamberski N. Nontuberculous Mycobacteria: Potential for Zoonosis. Zoo & Wild Animal Medicine, CT4. Fowler, Miller 1999: 146-150.

Line, Scott W. Environmental enrichment for laboratory primates. JAVMA, 190 (7), Aril 1, 1987, pp.854-859.

Lowenstine LJ. Lymphotropic and Immunosuppressive Retroviruses of Nonhuman Primates: A Review and Update. Proc. American Assoc of Zoo Veterinarians. 1993: 51-60.

Maslow J. Tuberculosis and Other Mycobacteria as Zoonoses. Proc American Assoc. of Zoo Veterinarians 1997:110-115.

Montali RJ. B Virus in Zoo Macaques: Current Issues. Proc. Joint Conference- American Assoc of Zoo Vets / Wildlife Disease Assoc / American Assoc. of Wildlife Vets. 1995: 265-267.

NIH policy manual: 3044-2- Protection of NIH Personnel Who Work With Nonhuman Primates 1993; Chapter 3044-2;OD/OIR 496-4920.

Nonhuman Primate Spumavirus Infections Among Persons with Occupational Exposure - United States, 1996. MMWR Vol. 46, No. 6, February 14, 1997.

Ostrowski, SR., Leslie MJ., Parrott T., Abelt S., Piercy PE. B-Virus from Pet Macaque Monkeys: An Emerging Threat in the United States? Emerging Infectious Diseases Vol. 4, No. 1, January-March 1998.

Pernikoff DS. Orkin J. Bacterial Meningitis Syndrome: An Overall Review of the Disease Complex and Considerations of Cross Infectivity Between Great Apes and Man. 1991 Proceedings - American Assoc. of Zoo Veterinarians. p. 235-241.

Perspectives in Disease Prevention and Health Promotion Guidelines top Prevent Simian Immunodeficiency Virus Infection in Laboratory Workers and Animal Handlers. MMWR, November 18, 1998 / 37(45); 693-694, 699-704.

Quesenberry KE. Hillyer EV. Veterinary Clinics of North America - Small Animal Practice. January 1994; 121-156.

Renquist DM. Whitney RA. Zoonoses Acquired From Pet Primates. http://pin.primate.wisc.edu/aboutp/pets/zoonoses.html: Source: Vet. Clinics of North America: Small Animal Practice 1987; 17(1): 219-240.

Roberts JA. Occupational Health Concerns with Nonhuman Primates in Zoological Gardens. J of Zoo and Wildlife Med 1995; 26(1): 10-23.

Rothman, J. and D.D. Bowman. A Review of the endoparasites of mountain gorillas, IN: Companion and Exotic Animal Parasitology, Bowman D.D. (Ed.) IVIS Website.

Sandstrom PA. Phan, KO., Switzer WM., Fredeking T., Chapman L., Heneine W., Folks T. Simian Foamy Virus Infection Among Zoo Keepers. Lancet, Vol 355, No. 9203, 12 February 2000.

Schweitzer M., Falcone V., Gange J., Turek R., Neumann-Haefelin D. Simian Foamy Virus Isolated from an Accidentally Infected Human Individual. Journal of Virology, Vol. 71, No. 6., June 1997.

Schultz KT, Benveniste R, Bridson WE, Houser WD, Uno H, Warner TFCS. Pathologic and Virologic Description of Three Cases of Type D Retrovirus Infection in Rhesus Monkeys and a Brief Review of Nonhuman Primate Retroviruses. Zoo Biology Supplement. 1989: 1:77-87.

Seroconversion to Simian Immunodeficiency B virus in Two Laboratory Workers. MMWR September 11, 1992 / 41(36)

Shellabarger WC. Zoo Personnel Health Program Recommendations, American Assoc of Zoo Veterinarians, Infectious Diseases Committee: 6/94:1-17.

Shellabarger WC. Overview of Primate Viral Zoonotic Diseases & Their Prevention. Proc. American Assoc. Of Zoo Veterinarians 1991:224-234.

Sleeman JM. Cameron K. Mudakikwa AB. Nizeyi JB. Anderson S. Cooper JE. Richardson M. Macfie EJ. Hastings B. Foster JW. J. Zoo and Wildlife Med. 2000: 31(1): 9-14.

Sleeman, Jonatha M. Determining the human diseases transmissible to the great apes of Western Uganda. Proceedings of the AAZB and IAAAM Joint Conference, 2000: 36-38.

Walsh, Peter D., et al. Catastrophic ape decline in western equatorial Africa. Nature, v.422, 10 April 2003: 611-614.

Weiss, RA. Retroviral Zoonoses. Nature Medicine, Vol. 4, No. 4, April 1998.

Whitney RA. Primate Medicine and Husbandry, Symposium on Non-Domestic Pet Medicine. Veterinary Clinics of North America: Small Animal Practice-Vol. 9. No. 3, August 1979

Wolfe, Nathan D., et al. Wild primate populations in emerging infectious disease research: the missing link? Emerging Infectious Diseases. Vol 4 (2), April-June, 1998. http://www.cdc.gov/ncidod/eid/vol4no2/wolfe.htm